

15100033D

HOUSE BILL NO. 1750

Offered January 14, 2015

Prefiled January 12, 2015

A *BILL to amend the Code of Virginia by adding in Chapter 34 of Title 54.1 an article numbered 4.1, consisting of sections numbered 54.1-3442.1 through 54.1-3442.4, relating to expanded access to investigational drugs.*

Patrons—Ransone, Albo, Bell, Richard P., Bloxom, Cole, DeSteph, Edmunds, Fariss, Fowler, Head, Helsel, Hope, Howell, James, Keam, Minchew, O'Bannon, Orrock, Peace, Pillion, Ramadan, Robinson, Sickles, Stolle and Wilt

Referred to Committee on Health, Welfare and Institutions

Be it enacted by the General Assembly of Virginia:

1. That the Code of Virginia is amended by adding in Chapter 34 of Title 54.1 an article numbered 4.1, consisting of sections numbered 54.1-3442.1 through 54.1-3442.4, as follows:

*Article 4.1.**Expanded Access to Investigational Drugs, Biological Products, and Devices.***§ 54.1-3442.1. Definitions.**

As used in this article, unless the context requires a different meaning:

"Investigational drug, biological product, or device" means a drug, biological product, or device that has successfully completed Phase I of a clinical trial, but has not been approved for general use by the U.S. Food and Drug Administration and remains under investigation in a clinical trial.

"Terminal condition" means a condition caused by injury, disease or illness from which, to a reasonable degree of medical probability, a patient cannot recover and (i) the patient's death is imminent or (ii) the patient is in a persistent vegetative state.

§ 54.1-3442.2. Eligibility for expanded access to investigational drugs, biological products, and devices; written, informed consent to treatment.

A. A person shall be eligible for expanded access to investigational drugs, biological products, or devices if:

1. He has a terminal condition, attested to by his treating physician and confirmed by a second physician not previously involved in the treatment of the patient who has conducted an independent examination of the patient. However, in cases in which the treating physician is board-certified in an appropriate specialty related to the treatment of the patient's terminal condition, confirmation by a second physician shall not be required;

2. Either (i) all treatment options approved by the U.S. Food and Drug Administration to treat his terminal condition have been exhausted or (ii) his treating physician and a second physician not previously involved in the treatment of the patient who has conducted an independent examination of the patient certify that the remaining treatment options approved by the U.S. Food and Drug Administration to treat his terminal condition are unlikely to produce a positive outcome for the patient and use of the investigational drug, biological product, or device to treat his terminal condition is the preferable treatment option;

3. The potential benefits of use of the investigational drug, biological product, or device to treat his terminal condition are greater than the potential risks of the use of the investigational drug, biological product, or device to treat his terminal condition;

4. He has received a recommendation from his physician for use of an investigational drug, biological product, or device for treatment of his terminal condition; and

5. He has given written informed consent to use of the investigational drug, biological product, or device for treatment of his terminal condition or, if the person is a minor or lacks capacity to provide informed consent, his parent or legal guardian has given written informed consent to the use of the investigational drug, biological product, or device for treatment of his terminal condition.

Documentation indicating that the person meets the criteria for eligibility for expanded access to investigational drugs, biological products, or devices shall be provided by the person's treating physician and shall be included in the patient's medical record.

B. Written informed consent to use of an investigational drug, biological product, or device shall include:

1. An explanation of the currently approved products and treatments for the person's terminal condition;

2. A statement that (i) all treatment options approved by the U.S. Food and Drug Administration to

INTRODUCED

HB1750

57 *treat his terminal condition have been exhausted or (ii) in the opinion of his treating physician and a*
58 *second physician who has conducted an independent examination of the patient, the remaining treatment*
59 *options approved by the U.S. Food and Drug Administration to treat his terminal condition are unlikely*
60 *to produce a positive outcome for the patient and use of the investigational drug, biological product, or*
61 *device to treat his terminal condition is the preferable treatment option, in the opinion;*

62 3. *An explanation of the specific investigational drug, biological product, or device proposed for*
63 *treatment of the person's terminal condition;*

64 4. *A description of possible outcomes resulting from use of the investigational drug, biological*
65 *product, or device to treat the person's terminal condition, including a statement that new,*
66 *unanticipated, different, or worse symptoms might result from and that death could be hastened by the*
67 *proposed treatment, based on the treating physician's knowledge of the proposed treatment in*
68 *conjunction with an awareness of the patient's condition;*

69 5. *A statement that the person may be required to pay any costs associated with use of the*
70 *investigational drug, biological product, or device; and*

71 6. *A statement that the person or, if the person is a minor or lacks capacity to provide informed*
72 *consent, his parent or legal guardian, consents to the use of the investigational drug, biological product,*
73 *or device for treatment of his terminal condition.*

74 **§ 54.1-3442.3. Expanded access to investigational drugs, biological products, or devices; cost;**
75 **insurance coverage.**

76 A. *A manufacturer of an investigational drug, biological product, or device may make such*
77 *investigational drug, biological product, or device available to a person who meets the criteria set forth*
78 *in subsection A of § 54.1-3442.2; however, nothing in this article shall require a manufacturer of an*
79 *investigational drug, biological product, or device to make such investigational drug, biological product,*
80 *or device available to such person.*

81 B. *A manufacturer that makes an investigational drug, biological product, or device available to a*
82 *person who meets the criteria set forth in subsection A of § 54.1-3442.2 may provide the investigational*
83 *drug, biological product, or device to the person free of charge or may require the person to pay the*
84 *costs of, or the costs associated with, the manufacture of the investigational drug, biological product, or*
85 *device.*

86 C. *An insurer proposing to issue individual or group accident and sickness insurance policies*
87 *providing hospital, medical and surgical, or major medical coverage on an expense-incurred basis;*
88 *corporation providing individual or group accident and sickness subscription contracts; or health*
89 *maintenance organization providing a health care plan for health care services may provide coverage*
90 *for costs related to treatment of a person's terminal condition with an investigational drug, biological*
91 *product, or device; however, nothing in this article shall require an insurer proposing to issue*
92 *individual or group accident and sickness insurance policies providing hospital, medical and surgical,*
93 *or major medical coverage on an expense-incurred basis; corporation providing individual or group*
94 *accident and sickness subscription contracts; or health maintenance organization providing a health*
95 *care plan for health care services to provide coverage for costs related to treatment of a person's*
96 *terminal condition with an investigational drug, biological product, or device.*

97 **§ 54.1-3442.4. Limitation of liability.**

98 *Notwithstanding any other provision of law to the contrary, a health care provider who recommends*
99 *an investigational drug, biological product, or device to a person who meets the criteria set forth in*
100 *subsection A of § 54.1-3442.2 shall be immune from civil liability for any adverse action, condition, or*
101 *other outcome resulting from the patient's use of the investigational drug, biological product, or device,*
102 *absent gross negligence or willful misconduct.*